Analyst Upgrades

• DuPont (DD) was upgraded to buy from neutral at Goldman.
• UBS upgraded Deere (DE) to buy from neutral and AGCO (AGCO) to neutral from sell.
• Canadian Solar (CSIQ) was upgraded to outperform from neutral at Macquarie.
• Thoratec (THOR) and DTE Energy (DTE) were upgraded to overweight from equal weight at Barclays.
• NICE Systems (NICE) was upgraded to overweight from neutral at HSBC.
• Deutsche Bank upgraded Copa Holdings (CPA) to buy from hold.
• BofA/Merrill upgraded Nu Skin (NUS) to buy from neutral.
• Continental Resources (CLR) was upgraded to buy from hold at Jefferies.

Analyst Upgrades

• FBR Capital upgraded Adobe Systems (ADBE) to outperform from market perform to reflect valuation following the recent pullback in shares, as well as the upcoming release of the company's CS5 product. The firm raised its price target for the stock to $39 from $36.
• Keefe Bruyette upgraded Zenith National (ZNT) to market perform from underperform following the company's merger agreement with Fairfax Financial. The firm thinks the offer is a strong price to receive for Zenith National shareholders.
• Kaufman Bros. upgraded Infosys (INFY) to buy from hold as it believes the offshore applications outsourcing market is picking up. The firm raised its target price for shares to $67 from $58.
• Ventas (VTR) was upgraded to buy from neutral at BofA/Merrill.
• Liz Claiborne (LIZ) was upgraded to buy from hold at KeyBanc.
• iStar Financial (SFI) was upgraded to hold from sell at Citigroup.

• Citigroup upgraded Procter & Gamble (NYSE:PG) to Buy from Hold after meeting with management as it believes a more aggressive strategy will lead to the company regaining market share. Citi raised its target on shares to $66 from $54.
  
• Piper Jaffray upgraded Allscripts (NASDAQ:MDRX) to Overweight from Neutral after learning the company signed a large contract with North Shore Long Island Jewish Hospital. Piper now sees upside to estimates and raised its target on shares to $22.50 from $14.
  
• UBS upgraded Amedisys (NASDAQ:AMED) to Buy from Neutral following a review of the Senate Finance Committee's healthcare proposal, which they view as "benign." The firm raised its target to $57 from $46.
• Daimler (NYSE:DAI) was upgraded to Outperform from Market Perform at Bernstein.
  
• Boston Private (NASDAQ:BPFH) was upgraded to Outperform from Market Perform at Keefe Bruyette.
  
• E-Trade (NASDAQ:ETFC) was upgraded to Buy from Neutral at Goldman.